Sancilio Pharmaceuticals Company, which markets, licenses and develops products based on its lipid drug delivery technology, filed on Monday with the SEC to raise up to $86 million in an initial public offering.
The Riviera Beach, FL-based company, which was founded in 2006 and booked $22 million in revenue for the 12 months ended June 30, 2015, plans to list on the Nasdaq under the symbol SPCI. Sancilio Pharmaceuticals initially filed confidentially on May 14, 2015. UBS Investment Bank, Piper Jaffray, JMP Securities and FBR Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
